Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278866

—

a19b7db2-872c-5a1e-8378-1f58af01bfd7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • IL6_JAK_STAT3_SIGNALING+0.300
  • ALLOGRAFT_REJECTION+0.270
  • INFLAMMATORY_RESPONSE+0.260
  • COMPLEMENT+0.240
  • INTERFERON_GAMMA_RESPONSE+0.240
  • KRAS_SIGNALING_UP+0.240
  • ANGIOGENESIS+0.220
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
  • INTERFERON_ALPHA_RESPONSE+0.200
  • TNFA_SIGNALING_VIA_NFKB+0.110

Top 10 suppressed

  • E2F_TARGETS-0.380
  • WNT_BETA_CATENIN_SIGNALING-0.370
  • G2M_CHECKPOINT-0.290
  • HYPOXIA-0.280
  • MYC_TARGETS_V2-0.280
  • HEDGEHOG_SIGNALING-0.230
  • ADIPOGENESIS-0.220
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
  • UV_RESPONSE_UP-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A8-A0A6-01A-12R-A056-07
breast-umap@18
—A0.805
294b2af92-0cfc-40b2-977d-6bd0fa4440d9
melanoma-umap@29
——0.773
3SAMN03290950
melanoma-umap@29
——0.751
4TCGA-97-A4LX-01A-11R-A24X-07
lung-landscapes@6
—cohortA10.743
5SRR8518300
breast-umap@18
—A0.735
620050035.Her2HRneg
breast-umap@18
—D0.732
7SRR8518255
breast-umap@18
—D0.732
8ff12dc45-d7ab-45ae-a049-2d20e3c546b6
melanoma-umap@29
——0.731
9C3N-02920
lung-landscapes@6
—cohortA10.731
10SRR13780265
lung-landscapes@6
—cohortMD20.729

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
ALLOGRAFT_REJECTION0.270Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
COMPLEMENT0.240Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.240Idelalisib— uncovered
KRAS_SIGNALING_UP0.240Inavolisib— uncovered
ANGIOGENESIS0.220Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.200Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.110Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
HEME_METABOLISM0.070Temsirolimus— uncovered
MYOGENESIS0.070Inavolisib— uncovered
PANCREAS_BETA_CELLS0.070Cobimetinib— uncovered
PROTEIN_SECRETION0.070Remibrutinib— uncovered
COAGULATION0.050Binimetinib— uncovered
IL2_STAT5_SIGNALING0.050Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.050Idelalisib— uncovered
APICAL_SURFACE0.030Temsirolimus— uncovered
APICAL_JUNCTION0.010Inavolisib— uncovered